Prostate cancer drug shows promise for kidney cancer in new trial

This study tests a radioactive drug, 177Lu-PSMA-617, in people with advanced kidney cancer that has spread and worsened despite standard treatments like immunotherapy and targeted therapy. The drug targets a protein called PSMA found on kidney cancer cells, delivering radiation directly to tumors. About 48 participants who test positive for PSMA will receive up to six doses over six weeks each. The goal is to see if the drug can shrink tumors and control the disease, while monitoring side effects like fatigue, nausea, and blood changes.